SEC Comment Letter for DiaMedica Therapeutics Inc. (DMAC) (CIK 0001401040) (DMAC) — Jan 6, 2020
DiaMedica Therapeutics Inc. (DMAC) (CIK 0001401040)
Date: Jan. 6, 2020 · CIK: 0001401040 · Accession: 0000000000-20-000113
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-235775
Letter
January 6, 2020 Rick Pauls President and Chief Executive Officer DiaMedica Therapeutics Inc. 2 Carlson Parkway, Suite 260 Minneapolis, MN 55447 Re:DiaMedica Therapeutics Inc. Registration Statement on Form S-3 Filed January 2, 2020 File No. 333-235775 Dear Mr. Pauls: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at 202-551-2544 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Amy E. Culbert, Esq.
Show Raw Text
January 6, 2020
Rick Pauls
President and Chief Executive Officer
DiaMedica Therapeutics Inc.
2 Carlson Parkway, Suite 260
Minneapolis, MN 55447
Re:DiaMedica Therapeutics Inc.
Registration Statement on Form S-3
Filed January 2, 2020
File No. 333-235775
Dear Mr. Pauls:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jeffrey Gabor at 202-551-2544 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Amy E. Culbert, Esq.